Previous 10 | Next 10 |
A new product candidate, SB207, to target anti-viral opportunities Pre-IND meeting anticipated in December 2019 Development of SB207 to be focused on indications with unmet patient need, such as external genital warts MORRISVILLE, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Novan, ...
MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, has been...
Funds to progress women’s health product candidate, WH504 Additive to recently announced NIH grant for WH602 Women’s health initiative to focus on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the ...
The following slide deck was published by Novan, Inc. in conjunction with this Read more ...
MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Compensation Committee of Novan’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of its common stock to a newly-hire...
MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the “Agreement”) of up to $25 million with Aspire Capital Fund, LLC (“Asp...
Underscores Company’s preparation for potential NDA submission for SB206 in molluscum Role to lead cross-functional coordination of key activities and timelines for the program SB206 top line results are expected no later than early in the first quarter of 2020 MORRISVIL...
MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York on Monday, September 9, 2019. Participation will include a Company ...
Company has received NIH federal grant of approximately $223,000 Anticipates additional federal grant of approximately $1.0 million Women’s health initiative to focus on potential HPV related onco-virus therapeutics Mechanistic rationale supported by recent University of A...
Company entered into negotiations with third party to transfer lease obligation Non-binding letter of intent signed 60-day exclusivity period to finalize details A successful transaction would lead to a reduction in legacy infrastructure and associated costs MORRISVILLE, N...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...